Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
With a commercial presence in 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.
Annual Results 2020
Kedrion reaches a Turnover of EUR 697.2 and, despite COVID-19, raises to 13.8% its Reported EBITDA at EUR 95.9 million
[wpdatatable id=15 table_view=regular]